Mucin secretion activity of gastric cancer as a prognostic factor: a clinicopathological analysis.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Manfredi Andreina, Cassone Giulia, Izzo Raffaella, Dallagiacoma Gloria, Felicetti Mara, Cariddi Adriana, Berti Alvise, Giollo Alessandro, Nannini Carlotta, Bettio Silvano, Monti Sara, Conticini Edoardo, Govoni Marcello, Quartuccio Luca, Argolini Lorenza Maria, Kaleci Shaniko, Emmi Giacomo, Dejaco Christian, Padoan Roberto, Dagna Lorenzo, Rossini Maurizio, Cantini Fabrizio, Montecucco Carlomaurizio, Frediani Bruno, De Vita Salvatore, Caporali Roberto, Muratore Francesco, Sebastiani Marco, Salvarani Carlo, Study Group of the Italian Society for Rheumatology (SIR)
Аннотация
METHOD: This retrospective study included 88 AGC patients who received ICIs combined with chemotherapy. Inflammatory and nutritional indicators from patients before and after two cycles of treatment were collected. Finally, the correlations between these indicators and the clinical response and survival of AGC patients with ICI treatment were examined.
RESULTS: The results revealed that an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0, neutrophil count to lymphocyte count ratio (NLR) < 2.84, platelet count to lymphocyte count ratio (PLR) < 82.23, lymphocyte count to monocyte count ratio ≥ 2.35, the hemoglobin, albumin, lymphocyte and platelet score (HALP) ≥ 31.17, prognostic nutritional index (PNI) ≥ 46.53, albumin ≥ 41.65, the decreased HALP group and the decreased PNI group were significantly correlated with improved objective response rate. Additionally, an ECOG PS score of 0, NLR < 2.84 and the decreased HALP group was associated with a superior disease control rate. Meanwhile, an ECOG PS score of 0 (progression-free survival (PFS): P = 0.003; overall survival (OS): P = 0.001) and decreased PLR following treatment (PFS: P = 0.011; OS: P = 0.008) were significant independent predictors of PFS and OS. Lastly, a systemic immune inflammation index ≥ 814.8 was also a positive independent predictor of OS among AGC patients.
CONCLUSION: Our study supports the potential of inflammatory and nutritional factors to serve as predictors of the efficacy and prognosis in patients undergoing ICI-based therapies for AGC. However, further investigations are necessary to validate these findings.